Trial Profile
An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patients With Cushing's Disease
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Pituitary ACTH hypersecretion
- Focus Therapeutic Use
- 15 Sep 2011 New trial record